Format

Send to

Choose Destination
Curr Top Microbiol Immunol. 2010;338:129-43. doi: 10.1007/978-3-642-02215-9_10.

Dengue vaccine candidates in development.

Author information

1
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. adurbin@jhsph.edu

Abstract

Each of the DENV serotypes can cause the full spectrum of dengue illness. Epidemiological studies have implicated preexisting heterotypic DENV antibody as a risk factor for more severe disease upon secondary DENV infection. For these reasons, a successful DENV vaccine must protect against all four DENV serotypes. Live attenuated DENV vaccine candidates are the furthest along in development and clinical evaluation. Two live attenuated tetravalent vaccine candidates are in Phase 2 clinical trials in DENV endemic regions. Numerous other vaccine candidates including inactivated whole virus, recombinant subunit protein, DNA and virus-vectored vaccines are also under development. Those DENV vaccine candidates that have been evaluated in preclinical animal models or in clinical trials will be discussed.

PMID:
19802583
DOI:
10.1007/978-3-642-02215-9_10
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center